Janssen Vaccines & Prevention B.V. clinical trials

Acquired by Johnson & Johnson, Feb 22, 2011 · source ↗

The registry lists 49 studies whose lead sponsor is Janssen Vaccines & Prevention B.V.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 13, 2025.

Studies

Recruiting first, then most recently updated. Showing 49 of 49. All Johnson & Johnson studies →

• A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and OlderCompletedNCT04908683Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy AdultsCompletedNCT05901636Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult ParticipantsCompletedNCT02543567Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in InfantsCompletedNCT03929757Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of AgeCompletedNCT03303625Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected AdultsCompletedNCT02935686Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 YearsCompletedNCT05101486Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and OlderTerminatedNCT05327816Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV InfectionCompletedNCT05070546Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and OlderCompletedNCT05071313Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and OlderTerminatedNCT03982199Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)CompletedNCT04765384Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older AdultsCompletedNCT04453202Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Ad26.COV2.S and Influenza Vaccines in Healthy AdultsCompletedNCT05091307Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years OldCompletedNCT05083585Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and OlderCompletedNCT03502707Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult ParticipantsCompletedNCT04228783Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected AdultsCompletedNCT02788045Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Ad26.COV2.S in Adults (COVID-19)CompletedNCT04436276Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years InclusiveCompletedNCT05007080Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in AdultsCompletedNCT04614948Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult ParticipantsCompletedNCT04505722Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy AdultsCompletedNCT04908722Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of AgeCompletedNCT03606512Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the CervixTerminatedNCT03610581Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old AdultsCompletedNCT03334695Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable HealthCompletedNCT03339713Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected AdultsCompletedNCT02919306Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) PreventionCompletedNCT02315703Phase 1/2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-FiloCompletedNCT02598388Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2CompletedNCT04999111Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral TreatmentCompletedNCT03307915Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected AdultsCompletedNCT02685020Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization ScheduleCompletedNCT03566940Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant WomenCompletedNCT04556526Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy AdultsCompletedNCT03032588Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender IndividualsCompletedNCT03964415Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-FiloTerminatedNCT02661464Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and AdolescentsCompletedNCT04535453Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan AfricaTerminatedNCT03060629Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-FiloCompletedNCT02509494Phase 3

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) AdultsCompletedNCT02564523Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study of Ad26.COV2.S in Healthy Adults (COVID-19)CompletedNCT04894305Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsCompletedNCT02416453Phase 2

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult VolunteersCompletedNCT03356561Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in AdultsCompletedNCT03795441Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable HealthCompletedNCT02926430Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy AdultsCompletedNCT02860650Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson

• A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsCompletedNCT02325050Phase 1

  Sponsor listed in the registry: Janssen Vaccines & Prevention B.V. · First submitted after Janssen Vaccines & Prevention B.V. became part of Johnson & Johnson